TABR Capital Management LLC Buys New Stake in Bristol Myers Squibb Company $BMY

TABR Capital Management LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, HoldingsChannel reports. The fund bought 30,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,624,000.

Several other hedge funds also recently bought and sold shares of the stock. Elevation Wealth Partners LLC lifted its position in shares of Bristol Myers Squibb by 44.5% in the fourth quarter. Elevation Wealth Partners LLC now owns 1,117 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 344 shares in the last quarter. Brave Asset Management Inc. purchased a new stake in Bristol Myers Squibb during the 4th quarter worth about $237,000. Spartan Planning & Wealth Management acquired a new position in Bristol Myers Squibb in the 4th quarter valued at about $217,000. O Keefe Stevens Advisory Inc. purchased a new position in Bristol Myers Squibb in the 4th quarter valued at about $225,000. Finally, Elmwood Wealth Management Inc. purchased a new position in Bristol Myers Squibb in the 4th quarter valued at about $258,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EMA approvals expanded Opdivo’s use into frontline Stage III/IV classical Hodgkin’s lymphoma for patients 12+, strengthening BMY’s oncology franchise and near‑term revenue potential. Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo US FDA approves Bristol Myers Squibb’s cancer drug for Hodgkin’s lymphoma
• Positive Sentiment: Sotyktu (BMY) received a label expansion into psoriatic arthritis, broadening BMY’s immunology franchise and helping offset pressure from legacy oncology and cardiovascular patent cliffs. Will the Recent Label Expansion of BMY’s Sotyktu Boost Its Prospects?
• Positive Sentiment: BMY advanced its protein‑degradation program: first‑in‑human dosing of BMS‑986506 for clear cell renal cell carcinoma triggered a $10M milestone to Evotec, signaling pipeline progress and potential long‑term upside if early data read out well. Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration
• Neutral Sentiment: HSBC nudged its price target to $60, a modest analyst upgrade that signals some confidence but is unlikely to drive large near‑term moves on its own. HSBC Boosts Bristol Myers Squibb (NYSE:BMY) Price Target to $60.00
• Neutral Sentiment: BMY scheduled Q1 2026 results for April 30 — a near‑term event that could reprice the stock depending on revenue and EPS versus guidance/expectations. Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
• Neutral Sentiment: Coverage pieces (Schaeffer, Zacks) have highlighted BMY as a recommended pick or trending ticker, which can lift interest but may already be priced in. Top Stock Picks of 2026: Bristol-Myers Squibb Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
• Negative Sentiment: Technical weakness flagged by a potential “death cross” (50‑day moving average crossing below 200‑day) can prompt selling by trend‑followers and contributed to the down‑pressure. These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Bristol Myers Squibb Price Performance

BMY opened at $57.42 on Monday. The company’s 50 day simple moving average is $58.60 and its 200 day simple moving average is $51.87. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The stock has a market capitalization of $116.93 billion, a PE ratio of 16.64, a P/E/G ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period last year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMY. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Leerink Partners lifted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Scotiabank reissued a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $61.41.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.